Positive Phase 1b results for ATX-304 suggest sc

Positive Phase 1b results for ATX-304 suggest sc

Phase 2 trial of leramistat targets sarcopenia,

Australian healthtech Everlab has raised $42 mil

New funding will support development of regenera

Stress-enduring cells offer a precision, homing-

Insilico Medicine announced completion of first-i

Oligomerix has received a $1.

Cambrian Bio presented Phase 1b human translation

NorthStrive Biosciences, a PMGC Holdings Inc.

Designs for Health launched Akkermansia Pro GLP-1

BPGbio presented clinical and translational findi

A once-daily patch could make one of pulmonary a

New data suggest MS 001 could help preserve musc

LNS8801 advances into the National Institute on

Dan DeBaun, founder of the largest authorized Be

A one-time CRISPR treatment dramatically reduced

Cognition Therapeutics announced on 16 June 2026

AlzeCure announced on 16 June 2026, that its Phas

Resolution Therapeutics has expanded its inflamma

ProJenX provided a development update for Proseti

Hangzhou Qihan Biotech announced that its off-the

Everlab has closed an oversubscribed AU$65 millio

LG AI Research signed a master agreement with D&D

Gero announced $17 million in new financing, brin

New supplement combines creatine, HMB and pomegr

A study from Muna Therapeutics suggests the brai

Non-invasive continuous hormone monitoring arriv

Men’s health company adds physician-prescribed

Stealth BioTherapeutics Holdings Inc.

Immorta Bio and TAM Global announced a preclinica

Restore Hyper Wellness, based in Austin, Texas, l

Telomir Pharmaceuticals announced the peer-review

BioAge Labs has dosed the first participant in QU

New financing backs a physics-based approach tha

New Longevity Science Foundation campaign aims t

Phase 2 study will assess whether RJx-01 can imp

New Michael J Fox Foundation grant backs a two-p

Alzheimer’s research may be entering its next

The biotech’s ultrasound platform could help o

Rznomics presented Phase 1/2a interim clinical re

Humacyte presented Phase 3 V012 results at the So

Halia Therapeutics announced that the U.S.

Regeneration Biomedical, Inc.

Elysium Health launched Creatine+, a three-in-one

Fractyl Health reports one-year data suggesting

New peer-reviewed findings suggest tackling two

Following promising results in disease treatment

Agemica founder recognized in King Charles III’s Birthday Honours as his AI-driven longevity platform advances toward in vivo testing. Professor Ronjon Nag, founder and CEO of longevity therapeutics company Agemica, has been appointed an Officer of the Order of the British Empire (OBE) in King Charles III’s Birthday Honours, being recognized for services to entrepreneurship and artificial intelligence [1]. The Birthday Honours are one of two major honours lists published each year as part of the UK’s national honors system, recognizing contributions across science, business, public service and the arts. While the award reflects Nag’s broader career in AI and technology entrepreneurship, it arrives at a moment when his attention is increasingly focused on aging biology and the application of artificial intelligence to age-related disease. From speech recognition to aging biology Nag’s career spans four decades of AI development. Having built an early speech-recognition system while an undergraduate at the University of Birmingham, he went on to study at Cambridge, MIT and Stanford, later founding companies whose technologies contributed to speech, handwriting recognition and predictive text systems adopted across the mobile industry. Today, through Agemica, he is applying those computational tools to a different challenge: identifying biological targets shared across…

New biomarkers, existing drugs and decades of ce